The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2026 | Longitudinal liquid biopsy versus bone marrow assessment for monitoring MRD in frontline myeloma
Elena Zamagni, MD, PhD, University of Bologna, Bologna, Italy, discusses the potential of longitudinal liquid biopsy for monitoring residual disease in frontline multiple myeloma, highlighting the benefits of using peripheral blood techniques, such as mass spectrometry and circulating DNA, over bone marrow measurable residual disease (MRD) assessment. Dr Zamagni notes that these approaches can anticipate bone marrow relapse and should be conducted in parallel, allowing for tailored treatment based on MRD status and patient fitness. This interview took place at the 23rd International Myeloma Society (IMS) Annual Meeting in Glasgow, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
